Erratum: A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (Blood (2019) 133: 11 (1201-1204) DOI: 10.1182/blood-2018-11-886457)

P. Martin, N. L. Bartlett, K. A. Blum

Research output: Contribution to journalComment/debate

Abstract

In the conflict-of-interest disclosure paragraph on page 1203, the sentence “S.C.-K. served as a consultant for Vigilant.” is incorrect. Author Selina Chen-Kiang had no competing financial interests to declare. The error has been corrected in the online version of the article.

Original languageEnglish
Pages (from-to)908
Number of pages1
JournalBlood
Volume134
Issue number11
DOIs
StatePublished - Sep 12 2019

Fingerprint

Dive into the research topics of 'Erratum: A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma (Blood (2019) 133: 11 (1201-1204) DOI: 10.1182/blood-2018-11-886457)'. Together they form a unique fingerprint.

Cite this